241 related articles for article (PubMed ID: 27771290)
1. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
Nassereddine S; Nishihori T; Padron E; Mahfouz R; Bazarbachi A; Komrokji RS; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):7-13. PubMed ID: 27771290
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
3. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia.
Schwartz JR; Walsh MP; Ma J; Lamprecht T; Wang S; Wu G; Raimondi S; Triplett BM; Klco JM
Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 29891567
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress on Role of Gene Mutations in Prognostic Evaluation of Patients with Myelodysplastic Syndrome after Stem-Cell Transplantation--Review].
Hu YM; Cui S; Ji LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1330-1333. PubMed ID: 31418402
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of next generation sequencing in myelodysplastic syndromes.
Spaulding TP; Stockton SS; Savona MR
Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.
Kobbe G; Schroeder T; Rautenberg C; Kaivers J; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2019 Oct; 12(10):821-831. PubMed ID: 31322458
[No Abstract] [Full Text] [Related]
7. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Bacher U; Kohlmann A; Haferlach T
Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
[TBL] [Abstract][Full Text] [Related]
8. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Mishra A; Anasetti C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.
Odenike O; Onida F; Padron E
Am Soc Clin Oncol Educ Book; 2015; ():e398-412. PubMed ID: 25993202
[TBL] [Abstract][Full Text] [Related]
10. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
Condorelli A; Frigeni M; Quaresmini G; Salmoiraghi S; Pavoni C; Grassi A; Raviglione M; Civini A; Putelli A; Lussana F; Finazzi MC; Algarotti A; Micò MC; Spinelli O; Rambaldi A
Leuk Res; 2024 Jul; 142():107529. PubMed ID: 38820666
[TBL] [Abstract][Full Text] [Related]
11. [Pathophysiology of MDS: genomic aberrations].
Ichikawa M
Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
[TBL] [Abstract][Full Text] [Related]
12. The current and future role of stem cells in myelodysplastic syndrome therapies.
Kobbe G; Schroeder T; Haas R; Germing U
Expert Rev Hematol; 2018 May; 11(5):411-422. PubMed ID: 29547016
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Steensma DP
Best Pract Res Clin Haematol; 2017 Dec; 30(4):295-300. PubMed ID: 29156198
[TBL] [Abstract][Full Text] [Related]
14. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
Abdulbaki R; Pullarkat ST
Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
[TBL] [Abstract][Full Text] [Related]
15. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
16. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
17. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
19. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
20. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
